ReviewNature reviews. Urology2016
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.Cancer immunology, immunotherapy : CII · 2021Pooled it
- Trial
- Trial
- Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Mapping therapy-responsive immune ecotypes in clear cell renal cell carcinoma through integrative omics.Frontiers in immunology · 2026Review
- Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.Scientific reports · 2025Article
- AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma.Cell reports. Medicine · 2025Article
- Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study.BMC cancer · 2025Article
- Artificial Intelligence in Uropathology.Diagnostics (Basel, Switzerland) · 2024Review
- Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.Heliyon · 2024Review
- Decreased expression ofOncology letters · 2024Article
- Immunotherapy and Immune Infiltration in Patients with Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis.Genetics research · 2023Article
- APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma.Heliyon · 2022Article
- Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.Nature reviews. Urology · 2022Review
- Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma.Journal of immunology research · 2022Article
- Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer.Cancer medicine · 2021Observational
- Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.Signal transduction and targeted therapy · 2021Article
- The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advanced RCC still have limited overall survival. Increased understanding of the mechanisms of T cell-antigen recognition and function has led to the development of novel immunotherapies to treat cancer, chief among them inhibitors of checkpoint receptors - molecules whose function is to restrain the host immune response. In 2015, the FDA approved the first checkpoint inhibitor nivolumab for patients with advanced RCC following treatment with antiangiogenic therapy based on improved overall survival compared with the standard of care. Ongoing phase III trials are comparing checkpoint-inhibitor-based combination regimens with antiangiogenesis agents in the first-line setting. The field is evolving rapidly, with many clinical trials already testing several checkpoint inhibitors alone, in combination, or with other targeted therapies. In addition, different novel immune therapies are being investigated including vaccines, T-cell agonists, and chimeric antigen receptor T cells. Determining which patients will benefit from these therapies and which combination approaches will result in better response will be important as this field evolves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.